Treatment for Kidney Cancer: Options, Stages, and Outcomes

A kidney cancer diagnosis is life-altering, but advances in treatment have dramatically improved outcomes over the past two decades. Understanding the available treatment for kidney cancer at each stage empowers patients and families to make informed decisions, ask the right questions, and pursue the most effective care. The treatment landscape has expanded well beyond surgery alone, offering new hope even for advanced-stage disease.

According to the American Cancer Society, approximately 81,000 new cases of kidney cancer are diagnosed in the United States each year. Renal cell carcinoma (RCC) accounts for about 90 percent of kidney cancers in adults. This guide covers the major treatment for kidney cancer options, how they relate to disease stage, expected outcomes, and practical guidance for navigating your care.

Understanding Kidney Cancer Stages

Treatment decisions depend heavily on the stage of kidney cancer at diagnosis. The staging system used by oncologists ranges from Stage I to Stage IV:

• Stage I: Tumor is 7 cm or smaller and confined to the kidney. Five-year relative survival rate is approximately 93 percent.
• Stage II: Tumor is larger than 7 cm but still confined to the kidney. Five-year survival rate is approximately 70 percent.
• Stage III: Cancer has spread to nearby lymph nodes, the renal vein, or surrounding tissues but not to distant organs. Five-year survival rate is approximately 70 percent.
• Stage IV: Cancer has spread to distant organs such as the lungs, bones, liver, or brain. Five-year survival rate is approximately 13 to 15 percent, though this figure is improving with newer treatments.

Survival statistics are based on large populations and may not predict individual outcomes. Many factors influence prognosis, including the specific type of kidney cancer, overall health, and response to treatment.

Surgery: The Primary Treatment for Early-Stage Kidney Cancer

Surgery remains the cornerstone of treatment for kidney cancer that has not spread to distant organs. The type of surgery depends on the tumor’s size, location, and the patient’s overall health.

Partial Nephrectomy (Nephron-Sparing Surgery)

This procedure removes the tumor and a small margin of healthy tissue while preserving the rest of the kidney. According to the NIH, partial nephrectomy is the preferred surgical approach for tumors 7 cm or smaller (Stage I) when technically feasible. Benefits include:

• Preservation of kidney function
• Lower long-term risk of chronic kidney disease
• Comparable cancer control outcomes to radical nephrectomy for small tumors

Partial nephrectomy can be performed as open surgery, laparoscopically, or with robotic assistance. Robotic-assisted partial nephrectomy has become increasingly common due to shorter recovery times and improved precision.

Radical Nephrectomy

This procedure removes the entire kidney, often along with the surrounding fat, adrenal gland, and nearby lymph nodes. Radical nephrectomy is typically recommended for:

• Larger tumors (Stage II and some Stage III)
• Tumors that cannot be safely removed while preserving the kidney
• Tumors involving the renal vein or inferior vena cava

Most people can live a normal life with one functioning kidney, though monitoring of kidney function is important after surgery.

Active Surveillance

For very small tumors (typically under 3 cm) found incidentally in elderly patients or those with significant health conditions, active surveillance with regular imaging may be recommended instead of immediate surgery. This approach monitors the tumor with CT scans or MRIs at defined intervals and proceeds to treatment if the tumor shows concerning growth.

Ablation Therapies

For small kidney tumors in patients who are not good surgical candidates, ablation therapies destroy the tumor without removing it:

• Cryoablation: Freezes the tumor using extreme cold delivered through a needle inserted into the tumor under imaging guidance.
• Radiofrequency ablation (RFA): Uses high-energy radio waves to heat and destroy the tumor.

These minimally invasive options are typically reserved for tumors under 4 cm and are performed under imaging guidance (CT or ultrasound). While effective for small tumors, they carry a slightly higher local recurrence rate compared to surgery.

Systemic Therapies for Advanced Kidney Cancer

When kidney cancer has spread beyond the kidney (Stage IV) or has returned after initial treatment, systemic therapies that work throughout the body are the primary approach. The treatment of advanced kidney cancer has been revolutionized in recent years.

Immunotherapy

Immunotherapy has become a cornerstone of treatment for advanced kidney cancer. These drugs help the immune system recognize and attack cancer cells:

• Checkpoint inhibitors: Drugs like nivolumab (Opdivo), pembrolizumab (Keytruda), and ipilimumab (Yervoy) work by blocking proteins that prevent immune cells from attacking cancer. The combination of nivolumab and ipilimumab was shown in the CheckMate 214 trial (published in the New England Journal of Medicine) to significantly improve overall survival compared to targeted therapy alone in intermediate- and poor-risk patients.
• Combination immunotherapy plus targeted therapy: Regimens combining a checkpoint inhibitor with a targeted therapy drug (such as pembrolizumab plus axitinib or lenvatinib) have become first-line treatment for many patients with advanced RCC, according to National Comprehensive Cancer Network (NCCN) guidelines.

Targeted Therapy

Targeted therapy drugs interfere with specific molecular pathways that kidney cancer cells rely on to grow and survive:

• VEGF/VEGFR inhibitors: Drugs like sunitinib, pazopanib, cabozantinib, axitinib, and lenvatinib block the formation of new blood vessels that tumors need to grow. These have been a mainstay of advanced kidney cancer treatment for over a decade.
• mTOR inhibitors: Everolimus and temsirolimus target a protein involved in cell growth and division. They are typically used after other treatments have stopped working.
• HIF-2 alpha inhibitor: Belzutifan (Welireg) is a newer drug that targets the HIF-2 alpha pathway, which is abnormally active in many kidney cancers. It was FDA-approved for certain patients with advanced RCC.

Cytoreductive Nephrectomy

In some cases of metastatic kidney cancer, surgeons may remove the primary kidney tumor even though cancer has spread elsewhere. This cytoreductive nephrectomy can improve the effectiveness of subsequent systemic therapy in selected patients, though its role has become more nuanced with the advent of immunotherapy-based regimens.

Radiation Therapy

Kidney cancer cells are relatively resistant to radiation, so radiation therapy is not a primary treatment. However, it plays a role in specific situations:

• Treating brain metastases (stereotactic radiosurgery)
• Relieving pain from bone metastases
• Managing symptoms from tumors that cannot be surgically removed

Choosing a Treatment: What to Consider

Treatment decisions for kidney cancer involve several factors:

• Cancer stage and subtype: The most important determinant of treatment approach
• Overall health and fitness: Surgical candidates need adequate physical fitness for recovery
• Kidney function: Preserving kidney function is prioritized when possible
• Molecular and genetic features: Some tumors have specific characteristics that guide therapy selection
• Patient preferences: Quality of life considerations, treatment side effects, and personal values

Seek care from a multidisciplinary team that includes a urologic oncologist, medical oncologist, and radiation oncologist when appropriate. For help locating a specialist, see our guide on how to find an oncologist.

Clinical Trials

Clinical trials offer access to cutting-edge treatments that are not yet widely available. The NIH clinical trials database (ClinicalTrials.gov) lists hundreds of active kidney cancer trials testing new drugs, combinations, and approaches. Discuss clinical trial eligibility with your oncologist, particularly if standard treatments have not been effective or if you have a rare subtype.

When to See a Doctor

Many kidney cancers are found incidentally during imaging for other conditions. If you have been diagnosed, seek a second opinion at a comprehensive cancer center, particularly for advanced-stage disease.

Frequently Asked Questions

Can kidney cancer be cured?

Yes, kidney cancer that is detected early (Stage I or II) and treated with surgery has a high cure rate. The five-year survival rate for localized kidney cancer exceeds 93 percent. For advanced kidney cancer that has spread to distant organs, a cure is less likely, but long-term disease control is increasingly achievable with modern immunotherapy and targeted therapy combinations. Some patients with metastatic disease achieve complete or near-complete responses that last for years.

What is the survival rate for kidney cancer?

According to the American Cancer Society, the overall five-year relative survival rate for kidney cancer is approximately 77 percent across all stages. When broken down by stage at diagnosis: localized (Stage I-II) is about 93 percent, regional (Stage III) is about 72 percent, and distant (Stage IV) is about 15 percent. These numbers are improving as newer treatments become available.

What are the side effects of kidney cancer treatment?

Side effects depend on the treatment type. Surgery involves typical surgical risks (pain, infection, bleeding) plus potential impact on kidney function. Immunotherapy can cause immune-related side effects affecting the skin, gut, liver, lungs, or endocrine system. Targeted therapy commonly causes fatigue, diarrhea, high blood pressure, hand-foot syndrome, and thyroid dysfunction. Your oncology team will monitor and manage side effects throughout treatment.

Is chemotherapy used for kidney cancer?

Traditional chemotherapy is generally not effective against renal cell carcinoma and is rarely used. Kidney cancer cells have mechanisms that make them resistant to most chemotherapy drugs. Instead, immunotherapy and targeted therapy have replaced chemotherapy as the standard systemic treatments for advanced kidney cancer. Chemotherapy may occasionally be used for rare subtypes like collecting duct carcinoma.

How long does kidney cancer treatment take?

The timeline varies by treatment type. Surgery requires 4 to 6 weeks of recovery for most patients. Systemic therapies for advanced disease are typically continued for as long as they are working and tolerable, which can be months to years. Immunotherapy may be given for a defined period (often 2 years if the cancer responds well) or until disease progression. Your oncologist will establish a treatment schedule and monitoring plan tailored to your situation.

Practical Takeaway

Treatment for kidney cancer has advanced significantly, offering effective options at every stage of the disease. Early-stage cancers are often curable with surgery alone, while advanced cancers now benefit from powerful immunotherapy and targeted therapy combinations that can extend survival and improve quality of life. Work with a specialized oncology team, consider seeking care at a comprehensive cancer center, and discuss clinical trial options, especially for advanced disease. The most important step is getting diagnosed accurately, staged completely, and connected with experienced specialists who can guide your treatment journey. For more information on health conditions and treatment, visit our medical conditions guide.